A trial looking at pembrolizumab combined with enzalutamide for prostate cancer (KEYNOTE 641)

This trial was for men with prostate cancer that had spread and was getting worse despite having hormone therapy or having their testicles removed. This is called metastatic castration resistant prostate cancer.

The trial compared pembrolizumab and enzalutamide with a dummy drug (placebo) and enzalutamide.

People could join the trial between 2019 and 2022. The team presented the results at the 2023 ESMO conference.

There is a link to more information in the ‘Summary of results’ section below.